Advertisement
UK markets closed
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     
  • AIM

    771.53
    +3.42 (+0.45%)
     
  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     
  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     
  • Bitcoin GBP

    50,667.80
    +1,393.39 (+2.83%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +450.02 (+1.18%)
     
  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     

Unilever’s doomed £50bn GlaxoSmithKline bid was a ‘near-death experience’

Alan Jope , Unilever press image
Alan Jope , Unilever press image

Fund manager Terry Smith made a fresh attack on Unilever following the collapse of its bid for GlaxoSmithKline’s consumer-health unit, saying the Dove soap maker needs to focus more on fixing its own business.

In a letter to shareholders, the outspoken investor described the failed approach as a “near-death experience,” saying that Unilever CEO Alan Jope’s attempt to purchase the GSK consumer business is now “thankfully dead rather than the value of our investment.”

The broadside adds pressure on Jope, whose public defeat came after analysts implored him not to pursue Glaxo’s division and was a flashback to Kraft Heinz’s failed bid to acquire Unilever in 2017 for $143 billion.

ADVERTISEMENT

Unilever’s stock is trading near the level of Kraft Heinz’s bid five years later, Smith noted.

The head of Fundsmith, Unilever’s 13th largest investor, earlier said that the company had “lost the plot” in seeking to promote the sustainable ethos of brands such as Hellmann’s mayonnaise rather than focusing on financial returns.

“It seems to us that Unilever management’s response to its poor performance has been to utter meaningless platitudes to which it has now attempted to add major M&A activity,” Smith wrote in the letter. “What could possibly go wrong?”

A Unilever representative declined to comment.

A deal for the Glaxo brands would have been Unilever’s largest takeover ever and was intended to anchor the company’s pivot to focus on consumer health-care.

Jope set out that ambition internally after unifying the company’s dual-headquartered structure in London in 2020, which was indeed to facilitate major acquisitions and disposals.

Smith stopped short of calling for Jope’s resignation, although he suggested that the executives at the helm aren’t invested in a successful turnaround.

“We believe the Unilever management – or someone else if they don’t want the job - should surely focus on getting the operating performance of the existing business to the level it should be before taking on any more challenges,” Smith said.

He said that Unilever should have explicitly addressed vital points and explained them to investors before asking to be allowed to proceed with a bid, which could have prevented shares from crashing to their lowest level in five years as investors resoundingly rejected the company’s strategy.

“Instead we were faced with a statement that the bid worked based on financial metrics including the all-important return on capital.

"However, getting management to discuss what that number was, was like a dentist pulling a back tooth,” Smith wrote in the letter that he signed with Julian Robins.

Smith said Unilever did consult with Fundsmith.

Fund manager Nick Train said late last year Unilever’s growth had been “crushingly pedestrian.”